
Commentary|Articles|May 14, 2015
- NSCLC (Issue 7)
- Volume 7
- Issue 2
MET as a Secondary Driver in Lung Cancer
Author(s)D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.
Advertisement
D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.
<<<
View more from the NSCLC Special Report
Articles in this issue
about 11 years ago
MiR-34a Link to PD-L1 May Mean New Immunotherapy in NSCLCabout 11 years ago
Treating EGFR Exon 19 Deletions in NSCLC: Q&A With Benjamin P. Levy, MDabout 11 years ago
More Endpoints Not Necessarily Merrier in NSCLC Drug Trialsabout 11 years ago
Combining Bevacizumab With EGFR TKIs in Lung Cancerabout 11 years ago
Characteristics of Additional KRAS Subsets in Lung Cancerabout 11 years ago
US-Cuban Partnership Developing Anticancer Vaccine for NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































